A Randomized, Placebo-controlled, Single-Ascending Dose Phase Ia Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH-006 in Healthy Volunteers
Latest Information Update: 10 Apr 2023
At a glance
- Drugs HH-006 (Primary)
- Indications Hepatitis B; Hepatitis D
- Focus Adverse reactions
- Sponsors Huahui Health
Most Recent Events
- 06 Apr 2023 Status changed from recruiting to completed.
- 22 Dec 2022 Planned number of patients changed from 32 to 33.
- 22 Dec 2022 Planned End Date changed from 15 Jan 2023 to 30 Jan 2023.